ArticleFrontiers in medicine2025
A clinical study incorporating multimodal
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disorder characterized by the infiltration of pathological Langerhans cells into multiple organs, exhibiting significant clinical heterogeneity. Although standard chemotherapy regimens have markedly improved patient survival rates, several challenges remain, such as low response rates, high recurrence rates, and long-term sequelae in certain patients. This study aimed to integrate multimodal 18F-FDG PET/CT metabolic parameters, genetic markers, and clinical characteristics to evaluate and predict treatment efficacy and prognosis in patients with LCH. Methods: A retrospective analysis was conducted on clinical data and Results: Patients with disease progression or recurrence exhibited significantly higher SUVmax, TLR, MTV, and TLG values compared to those who responded to treatment. ROC curve analysis identified optimal cutoff values for predicting disease remission as follows: SUVmax = 7.5, TLR = 5.2, MTV = 25.0, and TLG = 150. The remission rates in the high-value groups for SUVmax, MTV, and TLG were significantly lower than those in the corresponding low-value groups, with the most pronounced differences observed in the MTV and TLG groups ( Conclusion: Baseline metabolic parameters derived from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.